Key result
Early recognition and rapid corticosteroids are critical for managing ICI myocarditis in RCC patients.
Why the study?
Immune checkpoint inhibitor-associated myocarditis is an uncommon but serious complication in renal cell carcinoma treatment, with early multisystem immune toxicity being difficult to recognize in older patients.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Early recognition and rapid initiation of corticosteroids are critical in managing suspected immune checkpoint inhibitor-associated myocarditis, especially in older patients presenting with multisystem toxicity.
BACKGROUND: Immune checkpoint inhibitors are widely used in the adjuvant treatment of renal cell carcinoma. Although immune-related adverse effects are well described, myocarditis remains an uncommon complication. Ealy multisystem immune-related toxicity after limited exposure to therapy is uncommon and may be difficult to recognize in older patients. CASE SUMMARY: An 84-year-old woman receiving adjuvant pembrolizumab for renal cell carcinoma presented with dyspnea shortly after her second dose. She was found to have a new left bundle branch block, with marked troponin elevation and mild left ventricular dysfunction. Additional findings were consistent with myositis, pneumonitis, and nephritis. Coronary angiography showed nonobstructive coronary disease. Pembrolizumab was discontinued, and high-dose corticosteroids were initiated, resulting in gradual clinical improvement. DISCUSSION: This case shows the early presentation of pembrolizumab-associated myocarditis with multisystem immune-related toxicity involvement in an elderly patient, and it highlights the importance of early recognition and multidisciplinary management. TAKE-HOME MESSAGE: Early recognition and rapid initiation of corticosteroids are critical in suspected immune checkpoint inhibitor-associated myocarditis.
No takes yet. Share an insight, caveat, or question.
Chennuri et al. (2026) conducted a case report in Renal cell carcinoma (n=1). Pembrolizumab was evaluated. An 84-year-old woman developed early pembrolizumab-associated myocarditis and multisystem immune toxicity after her second dose, which improved following discontinuation and high-dose corticosteroids.
Synapse has enriched 10 related papers. Consider them for comparative context: